Geri Ödemede Referans Fiyatlandırmanın Hipertansiyon İlaç Harcamalarına Etkileri: 2007-2012 Dönemi Değerlendirmeleri

Abstract

Determination of drug prices and reimbursement procedures are regulated by legislation in Turkey. Today, the retail price of drugs is determined by the external reference pricing system by the Ministry of Health. The reimbursement system is carried out by the Social Security Institution. Compulsory public reductions and extra discounts according to the preferences of drug companies the firms are applied for drugs within reimbursement system and public price is calculated. Reimbursement reference pricing procedures are also used for determination of reimbursement price of the drug in case drug is being in an equivalent group. In this study it was aimed to evaluate the effects of reimbursement reference pricing method on drug spending. Because of that integrated and interactive nature of pharmaceutical pricing and reimbursement process implemented in Turkey, this study was designed to examine the effects of drug politics on drug spending in the period 2007-2012.